Leukemia, T-Cell Clinical Trial
Official title:
A Phase II, Multi-Center Open-Label, Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia With an Option of Long-Term Forodesine Hydrochloride (BCX-1777) Use
BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their
growth. The Phase II trial is designed to study the effectiveness of BCX-1777 in treating
patients who have recurrent or refractory advanced T-cell leukemia.
Patients will receive an infusion of BCX-1777 on days 1-5. Treatment may be repeated every
week for up to six courses. Patients are not required to be hospitalized for the
administration of BCX-1777. Some patients may continue to receive an infusion of BCX-1777
twice a week for 6 weeks.
BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. The Phase II trial is designed to study the effectiveness of BCX-1777 in treating patients who have recurrent or refractory advanced T-cell leukemia. ;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00001533 -
Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine
|
Phase 1 | |
| Terminated |
NCT02518750 -
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
|
Phase 2 | |
| Completed |
NCT00001249 -
Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac
|
Phase 1 | |
| Recruiting |
NCT05619861 -
CAR-T Cells in the Treatment of Malignant Hematological Tumors
|
N/A | |
| Not yet recruiting |
NCT06345027 -
CHIMERIC ANTIGEN RECEPTOR TREATMENT TARGETING CD70 (SEVENTY)
|
Phase 1 |